Ahmed Mohanad A, Yassin Mohamad A
Department of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Department of Medical Hematology and Oncology, Hamad Medical Corporation, Doha, Qatar.
Case Rep Oncol. 2020 Jun 15;13(2):655-658. doi: 10.1159/000507755. eCollection 2020 May-Aug.
Idiopathic thrombocytopenic purpura (ITP) is a disease in which the immune system attacks platelets and causes decrease in its number exposing the patient to risk of bleeding. It is diagnosed by exclusion. Eltrombopag is a thrombopoietin receptor agonist which is used as second-line treatment for patients with ITP. The usual starting dose is 25 mg daily and maintenance dose is 75 mg daily. Little is known about the dose of eltrombopag in patients with sleeve gastrectomy since reduction in the amount of functioning gastrointestinal tract after gastric bypass surgery leads to decreased time to drug absorption and reduced drug bioavailability. Here we are reporting a 46-year-old female with ITP and sleeve gastrectomy who responded to low-dose eltrombopag 25 mg every other day, which is equivalent to 12.5 mg daily, and maintained adequate platelet counts on this dose.
特发性血小板减少性紫癜(ITP)是一种免疫系统攻击血小板并导致其数量减少,使患者面临出血风险的疾病。它通过排除法诊断。艾曲泊帕是一种血小板生成素受体激动剂,用作ITP患者的二线治疗药物。通常起始剂量为每日25毫克,维持剂量为每日75毫克。由于胃旁路手术后功能性胃肠道数量减少导致药物吸收时间缩短和药物生物利用度降低,关于接受袖状胃切除术患者使用艾曲泊帕的剂量知之甚少。在此,我们报告一名46岁患有ITP且接受了袖状胃切除术的女性,她对每隔一天服用25毫克低剂量艾曲泊帕(相当于每日12.5毫克)有反应,并在此剂量下维持了足够的血小板计数。